We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: monoclonal antibody
MedXY News
EnglishTag

monoclonal antibody

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Amlenetug Shows Potential in Slowing MSA Progression Despite Phase 2 Trial Missing Primary Endpoint
Neurologyamlenetugmonoclonal antibody

Amlenetug Shows Potential in Slowing MSA Progression Despite Phase 2 Trial Missing Primary Endpoint

By MedXY|Apr 28, 2026

The phase 2 AMULET trial evaluated amlenetug, an anti-α-synuclein monoclonal antibody, in MSA patients. While it did not meet its primary endpoint, the antibody showed a non-significant 19% slowing of disease progression with an acceptable

Human Monoclonal Antibody MAM01 for Malaria Prevention: Phase 1 Trial Insights and Context in Antimalarial Monoclonal Antibody Development
Clinical Updatesclinical trialmalaria

Human Monoclonal Antibody MAM01 for Malaria Prevention: Phase 1 Trial Insights and Context in Antimalarial Monoclonal Antibody Development

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
By MedXY|Nov 23, 2025

This review synthesizes evidence on MAM01, a monoclonal antibody targeting Plasmodium falciparum circumsporozoite protein, summarizing its first-in-human phase 1 trial demonstrating safety and protective efficacy, alongside contextual advan

Nirsevimab Cuts RSV Lower Respiratory Infections in Infants Without Replacing Other Viruses: Post‑hoc Analysis of the Phase 3 MELODY Trial
Infectious Diseasesinfantsmonoclonal antibody

Nirsevimab Cuts RSV Lower Respiratory Infections in Infants Without Replacing Other Viruses: Post‑hoc Analysis of the Phase 3 MELODY Trial

By MedXY|Nov 10, 2025

Post hoc analysis of the MELODY Phase 3 trial shows nirsevimab reduced RSV-associated lower respiratory tract infections and RSV coinfections in healthy term and late-preterm infants, with no signal of viral replacement by other respiratory

Clesrovimab: A Promising Monoclonal Antibody for Preventing RSV in Healthy Infants
Infectious Diseasesmonoclonal antibodyRSV

Clesrovimab: A Promising Monoclonal Antibody for Preventing RSV in Healthy Infants

By MedXY|Oct 9, 2025

A single dose of clesrovimab significantly reduces respiratory syncytial virus (RSV) infections and hospitalizations in healthy infants during their first RSV season, with a safety profile comparable to placebo.

Cendakimab: A Promising Therapeutic for Eosinophilic Esophagitis in Adolescents and Adults
GastroenterologyCendakimabEosinophilic Esophagitis

Cendakimab: A Promising Therapeutic for Eosinophilic Esophagitis in Adolescents and Adults

By MedXY|Oct 9, 2025

Cendakimab, a monoclonal antibody targeting IL-13, shows significant improvements in symptoms, histologic response, and endoscopic features in eosinophilic esophagitis, with a tolerable safety profile through 48 weeks.

Long-term Safety and Efficacy of Rabies Monoclonal Antibody and Vaccine for Post-Exposure Prophylaxis: Insights from a Phase 4 Trial in India
Infectious Diseasesclinical trialmonoclonal antibody

Long-term Safety and Efficacy of Rabies Monoclonal Antibody and Vaccine for Post-Exposure Prophylaxis: Insights from a Phase 4 Trial in India

By MedXY|Oct 3, 2025

A phase 4 randomized trial demonstrates that combining rabies monoclonal antibody with vaccine in category 3 exposures is safe, immunogenic, and effective in preventing rabies up to one year post-exposure.

Inebilizumab for Generalized Myasthenia Gravis: Results from a Phase 3 Randomized Trial
Clinical Updatesinebilizumabmonoclonal antibody

Inebilizumab for Generalized Myasthenia Gravis: Results from a Phase 3 Randomized Trial

By MedXY|Sep 30, 2025

A phase 3 trial shows inebilizumab, a CD19+ B-cell depleting antibody, improves function and reduces disease severity in generalized myasthenia gravis without increasing serious adverse events.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities